Cover Image
市場調查報告書

Quilizumab(氣喘治療藥):市場預測與分析

Quilizumab (Asthma) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 316088
出版日期 內容資訊 英文 67 Pages
訂單完成後即時交付
價格
Back to Top
Quilizumab(氣喘治療藥):市場預測與分析 Quilizumab (Asthma) - Forecast and Market Analysis to 2023
出版日期: 2014年08月31日 內容資訊: 英文 67 Pages
簡介

Roche所開發的quilizumab是抗M1 prime人體化單株抗體的一種,專為消除b細胞以免其進化成漿細胞,並產生免疫球蛋白(IgE)這個目標而設計。這個藥劑以與Novartis的Xolair(結合IgE並中和)不同的機制運作。IgE對於過敏性氣喘的惡化而言相當重要,擁有結合肥胖細胞和嗜鹼性粒細胞,引起氣喘發作這樣重要的作用。最後促進組織胺和前列腺素、白三烯等的釋放,引起呼吸道的發炎和障礙等。Roche已經穩固其氣喘生物醫藥品主要企業的地位,Quilizumab對該公司而言,是第二個進入臨床實驗的最後階段的開發平台生物醫藥品。

本報告提供氣喘的治療藥之一,Quilizumab的全球市場相關分析,提供氣喘概要和治療方法,競爭的企業、藥品概要,市場競爭概況,彙整Quilizumab的商品資訊(特色·功效·安全性等),全球主要國家的市場銷售額預測(今後10年份)等調查,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因與病情
    • 病因
    • 病理生理學
    • 預後
    • 生活品質(QoL)
  • 症狀

第4章 疾病管理

  • 診斷·治療概要
    • 診斷
    • 治療的指南,臨床診療,有代表性的處方藥
    • 臨床診療

第5章 競爭評估

  • 概要
  • 競爭企業的策略性評估

第6章 未滿足需求與市場機會

  • 概要
  • 為了管理嚴重氣喘的個體化治療
    • 未滿足需求
    • 差距分析
    • 市場機會
  • 改善病人依從性
  • 降低氣喘藥物的治療費用
  • 恰當的診斷兒童氣喘

第7章 開發平台評估

  • 概要
  • 臨床實驗中有前途的醫藥品

第8章 關於Quilizumab

  • 概要
  • 功效
  • 安全性
  • 給藥·劑型
  • 在臨床方面的潛在性地位
  • 在商業方面的潛在性地位
  • 價格設定和醫療費給付
  • SWOT分析
  • 預測

第9章 附錄

圖表一覽

目錄

GlobalData has released its new PharmaPoint Drug Evaluation report, "Quilizumab (Asthma) - Forecast and Market Analysis to 2023". The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

Roche's quilizumab is an anti-M1 prime humanized mAb designed to eliminate B cells that would otherwise develop into plasma cells and produce IgE. This is a different mechanism from binding to and neutralizing existing IgE, as does Novartis' Xolair. IgE is important in the development of allergic asthma, as it binds to mast cells and basophils, which play a significant role in the pathogenesis of asthma. IgE ultimately triggers the release of histamines, prostaglandins, and leukotrienes, which produce airway inflammation and obstruction. Anti-IgE therapy is designed to block IgE at the beginning of its cascade. Roche is already an established player in the biological segment of the asthma market, and this is its second biological pipeline product entering late-phase development.

Scope

  • Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Quilizumab including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Quilizumab for the top eight countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Asthma
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Quilizumab performance
  • Obtain sales forecast for Quilizumab from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines, Clinical Practice, and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Personalized Therapies to Control Severe Asthma
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Better Patient Compliance
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Lower Cost of Asthma Medications
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Proper Diagnosis of Asthma in Children
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development

8. Quilizumab

  • 8.1. Overview
  • 8.2. Efficacy
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical Positioning
  • 8.6. Potential Commercial Positioning
  • 8.7. Pricing and Reimbursement
  • 8.8. SWOT Analysis
  • 8.9. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed Asthma Patients
    • 9.4.2. Percent Drug-Treated Patients
    • 9.4.3. General Pricing Assumptions
    • 9.4.4. Generic Erosion
    • 9.4.5. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in This Study
  • 9.6. About the Authors
    • 9.6.1. Author
    • 9.6.2. Author/Reviewer
    • 9.6.3. Reviewer
    • 9.6.4. Global Head of Healthcare
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Symptoms of Asthma
  • Table 2: Treatment Guidelines for Asthma by Country
  • Table 3: Most Prescribed Drugs for Asthma by Class and Disease Severity in the Global Markets, 2013
  • Table 4: Dosing of Common ICSs for Adult Asthma Therapy to Achieve Equivalent Therapeutic Potency
  • Table 5: Recommended Low Daily Dose of ICSs in Children with Asthma Under Five Years of Age
  • Table 6: Leading Treatments for Asthma, 2014
  • Table 7: Unmet Need and Opportunity in Asthma
  • Table 8: Asthma - Late Stage Pipeline, 2014
  • Table 9: Product Profile - Quilizumab
  • Table 10: Efficacy of Quilizumab Versus Placebo
  • Table 11: Quilizumab SWOT Analysis, 2014
  • Table 12: Global Sales Forecasts ($) for Quilizumab, 2013-2023
  • Table 13: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1:Stepwise Disease Management Approach for Asthma in Adults
  • Figure 2: Stepwise Disease Management Approach for Asthma in Children Age Five and Younger
  • Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in Asthma, 2013-2023
Back to Top